Vittoriabio
3 known investors
Vittoria Biotherapeutics is a clinical-stage company developing next-generation autologous CAR T-cell immunotherapies for oncology and immunology, built on its Senza5 platform that uses CD5 signaling modulation and a 5-day manufacturing process. Its lead candidate, VIPER-101, is in a Phase 1 trial for T-cell lymphoma.
Investors · 3
Frequently asked questions
- What does Vittoriabio do?
- Vittoria Biotherapeutics is a clinical-stage company developing next-generation autologous CAR T-cell immunotherapies for oncology and immunology, built on its Senza5 platform that uses CD5 signaling modulation and a 5-day manufacturing process. Its lead candidate, VIPER-101, is in a Phase 1 trial for T-cell lymphoma.
- Who are Vittoriabio's investors?
- Vittoriabio's investors include BioAdvance, Global BioAccess Fund, Agent Capital.